Researchers indicated that among men age ≥66 with prostate cancer, organ transplant is associated with higher overall mortality but no observable difference in prostate cancer-specific mortality.
Recommendations defined when and how radiation therapy should be used to treat patients with basal cell carcinoma and cutaneous squamous cell carcinoma.
The breast cancer expert discussed 2 advances in HER2-positive breast cancer treatment that healthcare providers should look for.
Lawrence Feldman, MD, of the division of hematology and oncology in the department of medicine at the University of Illinois at Chicago, and a team of researchers received a grant to explore addiction, abuse, and new ways to prescribe opioids.
Patients recently diagnosed with ovarian cancer indicated that they would accept a moderately higher risk of complication and surgical mortality in exchange for higher overall survival.
Seattle Genetics announced the development after data was presented at the 2019 San Antonio Breast Cancer Symposium.
The combination of encorafenib and cetuximab has shown promise in clinical testing for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation.
The FDA granted accelerated approval to enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
The updated and expanded NCCN guidelines broaden the testing criteria, while clarifying who should be tested for genetic mutations.
The cancer risk and prevention expert discussed germline testing and the benefits it lends to patients with breast cancer.
The anti-PD-1 therapy was recommended as a treatment for certain patients with high-risk, non-muscle invasive bladder cancer.
The assistant professor from the University of Michigan talked about personalizing radiation treatment in patients with breast cancer and how genomic signatures can be used to identify the radiation needs of patients.
The PARP inhibitor was recommended as a first-line maintenance monotherapy for patients with germline BRCA-mutated metastatic pancreatic cancer.
A retrospective study found that 40% of all patients with metastatic colon cancer are not tested according to guideline recommendations for biomarker testing.
The hematology and medical oncology expert described the implementation of biosimilars into treating patients with breast cancer.